All Stories

  1. Role of paraoxonase 1 in organophosphate G-series nerve agent poisoning and future therapeutic strategies
  2. Polybodies: Next-generation clinical antibodies
  3. Broad-spectrum anti-cancer activity of fused human arginase variants
  4. Warfare Nerve Agents and Paraoxonase-1 as a Potential Prophylactic Therapy against Intoxication
  5. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies
  6. Treating liver cancer through arginine depletion
  7. Polyvalency: an emerging trend in the development of clinical antibodies
  8. Towards development of biobetter: L-asparaginase a case study
  9. Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics
  10. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status
  11. Development and characterization of fused human arginase I for cancer therapy
  12. Human arginase I: a potential broad-spectrum anti-cancer agent
  13. Fused human paraoxonase 1 as a prophylactic agent against organophosphate poisoning
  14. Polyspecificity - An emerging trend in the development of clinical antibodies
  15. Paraoxonase 1 as a potential prophylactic against nerve agent poisoning
  16. Types of Wound Dressings and Materials used in Mild to Moderately Exuding Wounds: A Review
  17. Apolipoprotein-mimetic Peptides: Current and Future Prospectives
  18. Immunomodulatory potential of apolipoproteins and their mimetic peptides in asthma: Current perspective
  19. Human arginase 1, a Jack of all trades?
  20. Therapeutic potential of ApoE-mimetic peptides in CNS disorders: Current perspective
  21. HDL, ApoA-I and ApoE-Mimetic Peptides: Potential Broad Spectrum Agent for Clinical Use?
  22. Optimization of medium composition to increase the expression of recombinant human interferon-β using the Plackett–Burman and central composite design in E. coli SE1
  23. Human Arginase I (Arg I)—A Potential Broad-spectrum Anti-cancer Agent: Perspectives and the Road Ahead
  24. APOE-Derived Peptides Attenuated Diabetes-Induced Oxidative Stress and Inflammation
  25. Is Human Paraoxonase 1 the Saviour Against the Persistent Threat of Organophosphorus Nerve Agents?
  26. Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics
  27. Antibiotic-free expression system for the production of human interferon-beta protein
  28. Towards Understanding the Catalytic Mechanism of Human Paraoxonase 1: Experimental and In Silico Mutagenesis Studies
  29. Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead
  30. Refolded Recombinant Human Paraoxonase 1 Variant Exhibits Prophylactic Activity Against Organophosphate Poisoning
  31. Toward Understanding the Catalytic Mechanism of Human Paraoxonase 1: Site-Specific Mutagenesis at Position 192
  32. Abstract 12419: Preclinical Safety and Efficacy of a Novel Thrombolytic Agent Administered by Rapid Bolus Injection: Clot Specific Streptokinase (CSSK/SMRX-11)
  33. Improving Properties of Recombinant SsoPox by Site-Specific Pegylation
  34. Expression and purification of biologically active recombinant human paraoxonase 1 from inclusion bodies of Escherichia coli
  35. Expression, purification and immobilization of recombinant AiiA enzyme onto magnetic nanoparticles
  36. Improving storage stability of recombinant organophosphorus hydrolase
  37. Interplay between amino acid residues at positions 192 and 115 in modulating hydrolytic activities of human paraoxonase 1
  38. Properties of apolipoprotein E derived peptide modulate their lipid-binding capacity and influence their anti-inflammatory function
  39. Stabilization Studies on Bacterially Produced Human Paraoxonase 1 for Improving Its Shelf Life
  40. Human Paraoxonase 1 as a Pharmacologic Agent: Limitations and Perspectives
  41. Apolipoprotein E Derived Peptides Inhibit the Pro-Inflammatory Effect of Lysophosphatidylcholine
  42. Oxidized-phospholipids in reconstituted high density lipoprotein particles affect structure and function of recombinant paraoxonase 1
  43. Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme
  44. Differential interaction of peptides derived from C-terminal domain of human apolipoprotein E with platelet activating factor analogs
  45. The Chemical Nature of the Polar Functional Group of Oxidized Acyl Chain Uniquely Modifies the Physicochemical Properties of Oxidized Phospholipid-Containing Lipid Particles
  46. Physicochemical properties of bacterial pro-inflammatory lipids influence their interaction with apolipoprotein-derived peptides
  47. Oxidized phospholipid content destabilizes the structure of reconstituted high density lipoprotein particles and changes their function
  48. Characterization of Oxidized Phospholipid containing Reconstituted High Density Lipoprotein Particle
  49. A Therapeutic Chemical Chaperone Inhibits Cholera Intoxication and Unfolding/Translocation of the Cholera Toxin A1 Subunit
  50. Closely related oxidized phospholipids differentially modulate the physicochemical properties of lipid particles
  51. Membrane lipid composition differentially modulates the function of human plasma platelet activating factor-acetylhydrolase
  52. Contribution of Subdomain Structure to the Thermal Stability of the Cholera Toxin A1 Subunit
  53. Oxidatively modified fatty acyl chain determines physicochemical properties of aggregates of oxidized phospholipids
  54. Stabilization of the Tertiary Structure of the Cholera Toxin A1 Subunit Inhibits Toxin Dislocation and Cellular Intoxication
  55. Peptide derived from the lipid binding domain of Group IB human pancreatic phospholipase A2 possesses antibacterial activity
  56. Membrane surface charge modulates lipoprotein complex forming capability of peptides derived from the C-terminal domain of apolipoprotein E
  57. Preferential binding of apolipoprotein E derived peptides with oxidized phospholipid
  58. Bax C-Terminal Peptide - Insights Into Membrane Interactions
  59. Conformational Instability of the Cholera Toxin A1 Polypeptide
  60. The Pertussis Toxin S1 Subunit Is a Thermally Unstable Protein Susceptible to Degradation by the 20S Proteasome
  61. Isoform-Specific Membrane Insertion of Secretory Phospholipase A2 and Functional Implications
  62. Structural and Functional Effects of Tryptophans Inserted into the Membrane-binding and Substrate-binding Sites of Human Group IIA Phospholipase A2
  63. Carbohydrate-induced modulation of cell membrane. VIII. Agglutination with mammalian lectin galectin-1 increases osmofragility and membrane fluidity of trypsinized erythrocytes
  64. Evidence for the Regulatory Role of the N-terminal Helix of Secretory Phospholipase A2 from Studies on Native and Chimeric Proteins
  65. Positioning Membrane Proteins by Novel Protein Engineering and Biophysical Approaches
  66. Membrane Fluidity Is a Key Modulator of Membrane Binding, Insertion, and Activity of 5-Lipoxygenase
  67. Modulation of Human 5-Lipoxygenase Activity by Membrane Lipids, by
  68. The N-terminal α-Helix of Pancreatic Phospholipase A2 Determines Productive-mode Orientation of the Enzyme at the Membrane Surface
  69. Modulation of Human 5-Lipoxygenase Activity by Membrane Lipids
  70. Oxidation of Goat Hepatic Galectin-1 Induces Change in Secondary Structure
  71. Involvement of a Nine-residue Loop of Streptokinase in the Generation of Macromolecular Substrate Specificity by the Activator Complex through Interaction with Substrate Kringle Domains
  72. Studies on a Doubleheaded Protease Inhibitor from Phaseolus mungo
  73. Carbohydrate induced modulation of cell membrane VII. Binding of exogenous lectin increases osmofragility of erythrocytes
  74. Carbohydrate induced modulation of cell membrane. VI. Binding of exogenous lectin induces susceptibility of erythrocytes to free radical damage: a spin label study